QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-summit-therapeutics-raises-price-target-to-45

HC Wainwright & Co. analyst Mitchell Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price ...

Core News & Articles

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also rais...

 why-summit-therapeutics-smmt-stock-is-rising-today

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net pro...

 summit-therapeutics-says-accepted-offers-from-multiple-investors-to-purchase-aggregate-of-1035m-shares-at-2270-per-share-for-aggregate-gross-proceeds-of-235m

All of Summit's Section 16 officers participated in the capital raise. A total of $79 million was raised by insiders, inclu...

 citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-19

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

 stifel-maintains-buy-on-summit-therapeutics-raises-price-target-to-25

Stifel analyst Bradley Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $14 to...

Core News & Articles

PLTR: 8% | Palantir Technologies shares are trading higher amid its addition to the S&P 500 index. TERN: 42% | Terns Pharma...

 summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-risk-of-disease-or-death-by-half

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free sur...

 hc-wainwright--co-maintains-buy-on-summit-therapeutics-raises-price-target-to-30

HC Wainwright & Co. analyst Mitchell Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price ...

Core News & Articles

 Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First...

 hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $16 pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION